π¬ Current Disease Focus:
Task Progress: 0%
π₯ Active Problem Solvers
0
π Experts collaborating globally
β‘ Current Task Assignment
𧬠Genetic Analysis
π Matching experts to specific tasks
π Resource Allocation by Research Phase:
π Data Analysis
π§ͺ Experimental Design
π¬ Clinical Trials
π Treatment Development
Heart failure is the most common hospital admission diagnosis and shows inc...
Status
Completed
Location
Department of Internal Medicine I, Jena University Hospital
Start Date
2019-09-29
Trial ID
NCT04049045
Treatments Being Tested
The objective of this study is to evaluate the efficacy and safety of tenel...
Status
Completed
Location
Seoul National University Hospital
Start Date
2022-09-27
Trial ID
NCT05504239
Purpose: The overall hypothesis of the study is that the benefits attained...
Status
Completed
Location
Mount Sinai Heart - Icahn School of Medicine at Mount Sinai
Start Date
2018-05-21
Trial ID
NCT03485222
Treatments Being Tested
Systemic lupus erythematosis (SLE) is a chronic, most probably auto-immune ...
Status
Recruiting
Location
Beni-Suef university hospital
Start Date
2024-01-22
Trial ID
NCT07700940
Treatments Being Tested
A proof-of-concept placebo-controlled trial to explore the acute and 14-day...
Status
Recruiting
Location
Yale University
Start Date
2023-09-11
Trial ID
NCT05726032
Treatments Being Tested
The addition of the SGLT2 inhibitor empagliflozin 10mg once daily to standa...
Status
Unknown
Location
Glasgow Royal Infirmary
Start Date
2022-09-16
Trial ID
NCT05020704
Treatments Being Tested
the pharmacokinetics, pharmacodynamics and safety and tolerability of singl...
Status
Completed
Location
1245.44.86001 Boehringer Ingelheim Investigational Site
Start Date
2011-03
Trial ID
NCT01316341
The hypothesis is that the SGLT-2 inhibitor empagliflozin reduces tissue so...
Status
Completed
Location
Clinical Research Center, Department of Nephrology and Hypertension, University of Erlangen-Nuremberg
Start Date
2017-07-01
Trial ID
NCT03128528
Treatments Being Tested
This study is to analyze whether the SGLT2-inhibitor empagliflozin or the I...
Status
Withdrawn
Location
Multiple Locations
Start Date
2022-06-24
Trial ID
NCT05174507
Treatments Being Tested
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are newly developed antih...
Status
Completed
Location
Cairo university hospitals
Start Date
2020-02-20
Trial ID
NCT05283057
Treatments Being Tested